Trial Profile
Prospective, open label, randomized phase II trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high risk neuroblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jul 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Sirolimus (Primary) ; Irinotecan; Temozolomide
- Indications Neuroblastoma
- Focus Therapeutic Use
- 06 Jun 2023 Primary endpoint has been met, (Progression-free survival (PFS), as per Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 02 Oct 2020 Status changed from recruiting to completed.